Table 5.
Main findings of the included studies on the incidence of endometrial cancer in BRCAm patients.
| Author | Total Patients | Age, yr [Mean ± SD/Median (Range)] † | Total EC | EC Histopathology (n. of Patients; %) | EC with Previous Breast Cancer | EC in Patients Using Tamoxifen/Tot Patients Using Tamoxifen | History of Breast Cancer | Number of BRCA Mutated Patients | EC with BRCAm | Follow-Up [Mean/Median (Range), yr] or Women-Years (Median) | EC Risk in BRCAm (SIR [95% CI, p]) | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FIGO Stage | Grade | BRCA 1 (BRCA1mEC/EC) | BRCA 2 (BRCA2mEC/EC) | Tot | |||||||||||
| Beiner et al. [30] | 857 | 54 (45–70) | 6 | I (4, 66%) II (1, 17%) NA (1, 17%) |
1 (4, 66%) 2 (1 (17%) 3 (1, 17%) |
5 | 0 | 4/226 | 551 | 619 (4/6) | 236 (2/6) | 857 | 6 | 3.3 (0.01–9.6) | 5.3 (p = 0.0011) |
| Casey et al. [13] | 101 | NA | 8 | NA | 1 (2, 25%) 2 (2, 25%) 3 (3, 38%) NA (1, 12%) |
6 | 3 | 2/8 | 6/8 | 89 (7/8) | 12 (1/8) | 101 | 8 | NA | NA |
| Kitson et al. [37] | 2609 | 20 (20–32) | 14 | I (5, 36%) II (1, 7%) III (2, 14%) NA (6, 43%) |
NA | NA | NA | NA | NA | 1350 (7/14) | 1259 (7/14) | 2609 | 14 | 59,199 (23.8) women years | 1.70 (0.74–3.33) |
| Laitman et al. [11] | 2627 | 43 ± 7.7 | 14 | NA | NA | 7 | 5 | 2/178 | 1240 | 1746 (10/14) | 1367 (4/14) | 2627 | 14 | 32.744 † women years 20.468 †† women years |
USC *** 14.29 (4.64–33.34, p < 0.001) Sarcoma *** 37.74 (10.28–96.62, p < 0.001) BRCA1 5.236 (2.659–9.382, p < 0.001) BRCA2 2.339 (0.743–5.642, p = 0.124) |
| Lee et al. [35] | 828 | 43 (34–52) | 5 | I (3, 60%) II (2, 40%) |
1 (2, 40%) 2 (1, 20%) 3 (2, 40%) |
3 | 0 | 3/160 | 419 | 438 (3/5) | 390 (2/5) | 828 | 5 | 9.0 | 2.45 (95% CI: 0.80–5.72, p = 0.11) BRCA1 2.87 (95% CI 0.59–8.43, p = 0.18) BRCA2 2.01 (95% CI 0.24–7.30, p = 0.52) |
| Minig et al. [36] | 359 | 49 ± 9.0 | 1 | I (1, 100%) | NA | 1 | 1 | NA | 225 | 223 (NA) | 141 (NA) | 359 | 1 | 2.4 (0.3–7.7) | NA |
| Reitsman et al. [14] | 315 | 43 (30–71) | 2 | I (2, 100%) | NA | 1 | 0 | 0/19 | 118 | 201 (1/2) | 114 (1/2) | 315 | 2 | 6 (0– 27) | 2.13 (0.24–7.69; p = 0.27) |
| Saule et al. [15] | 369 | BRCA1 47 ± 1.3 BRCA 2 53 ± 6.8 |
2 | IV (2, 100%) | NA | 0 | 2 | 0/5 | 0 | 238 (2/2) | 131 (0/2) | 369 | 2 | 1779 woman-years | 32.2 (11.5–116.4, p < 0.001) |
| Segev et al. [31] | 4456 | 43 | 17 | NA (17, 100%) | 1 (5, 29%) 2 (1, 6%) NA (11, 65%) |
10 | 1 | 8/697 | 1837 | 3536 (13/17) | 920 (4/17) | 4456 | 17 | 5.7 | 1.87, (1.13–2.94, p = 0.01) BRCA1 1.91 (1.06–3.19, p = 0.03) BRCA2 1.75 (0.55–4.23, p = 0.2) |
| Shu et al. [12] | 1083 | 46 (41–53) | 8 | I (5, 63%) II (2, 25%) III (1, 12%) |
NA | 4 | 5 | 3/273 | 727 | 630 (5/8) | 456 (3/8) | 1083 | 8 | 5.1 (3.0–8.4) | 1.9 (0.8–3.7, p = 0.09) |
| Thompson et al. [29] | 7106 ** | NA | 47 | NA | NA | NA | NA | NA | 1928 | 2245 (11/11) | 0 | 2245 | 11 | NA | 2.65 (1.69–4.16, p < 0.001) |
| Segev et al. [32] | 14,621 | 52 (23–67) **** | 83 | NA | NA | 46 | NA | 17/76 | 394/46 | 951 (62/83) | 76 (21/83) | 1027 | 83 | NA | NA |
| Zakhour et al. [33] | 257 | 46 (28–79) | 1 | II (1, 100%) | 3 (1, 100%) | NA | 0 | NA | 110 | 153 | 103 (1/1) | 257 | 1 | NA | NA |
| Bogani et al. [34] | 85 | 47 ± 8.2 | 1 | NA | NA | 1 | 0 | NA | 60 | 32 (1/1) | 25 | 57 | 1 | 1.5 ± 0.4 | NA |
BRCAm breast cancer gene mutated patient, EC endometrial cancer, USC uterine serous carcinoma, NA not available, BRCA1mEC breast cancer gene. One mutated patient with EC, BRCA2mEC breast cancer gene 2 mutated patient with EC. † women-years of follow up in BRCAm group. †† women-years of follow up in non-BRCA group. ** Thompson et al. included 11,847 patients, of whom 7106 were women. *** Risk in carriers group. **** Median age for cases.